|
RAD23B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.44020000000189E-05 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.45210510282823E-11 |
| Stage1-vs-Stage2 |
1.400200E-02 |
| Stage1-vs-Stage3 |
2.641800E-01 |
| Stage1-vs-Stage4 |
6.952200E-01 |
| Stage2-vs-Stage3 |
6.493900E-02 |
| Stage2-vs-Stage4 |
5.144100E-02 |
| Stage3-vs-Stage4 |
6.433000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
4.18130000000572E-05 |
| Normal-vs-Asian |
4.2440051473136E-11 |
| Caucasian-vs-AfricanAmerican |
8.807200E-01 |
| Caucasian-vs-Asian |
8.808200E-01 |
| AfricanAmerican-vs-Asian |
9.709800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62525548574877E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
1.890130E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
2.87869728055057E-11 |
| Normal-vs-Age(81-100Yrs) |
1.674010E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.354200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.097200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.387400E-04 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.887700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.892500E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.453590E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.935800E-01 |
| Classical-VS-Follicular |
7.64943663966733E-14 |
| Classical-VS-Other |
1.479150E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
6.86949999995079E-07 |
| Tall-VS-Other |
1.105990E-01 |
| Tall-VS-Normal |
2.98139957166654E-10 |
| Follicular-VS-Other |
3.958000E-01 |
| Follicular-VS-Normal |
3.89680000000281E-05 |
| Other-VS-Normal |
1.481990E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
1.83159998279336E-09 |
| N0-vs-N1 |
1.451200E-01 |
|
|
